Ost-müük Cerevel Therapeutics Holdings, Inc. - CERE CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.11 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 26.94 |
Avatud* | 25.72 |
Aastane muutus* | -4.56% |
Päeva ulatus* | 25.72 - 27.24 |
52 nädala ulatus | 19.86-41.46 |
Keskmine maht (10 päeva) | 830.10K |
Keskmine maht (3 kuud) | 12.64M |
Turukapitalisatsioon | 3.67B |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 156.66M |
Tulu | N/A |
EPS | -2.32 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | May 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 26.95 | 1.81 | 7.20% | 25.14 | 27.30 | 25.14 |
Jun 28, 2022 | 26.94 | -0.93 | -3.34% | 27.87 | 29.13 | 26.80 |
Jun 27, 2022 | 28.99 | 0.89 | 3.17% | 28.10 | 29.70 | 27.49 |
Jun 24, 2022 | 28.08 | -0.17 | -0.60% | 28.25 | 29.09 | 27.63 |
Jun 23, 2022 | 28.54 | 3.28 | 12.98% | 25.26 | 28.60 | 25.26 |
Jun 22, 2022 | 26.05 | 1.34 | 5.42% | 24.71 | 26.24 | 24.71 |
Jun 21, 2022 | 25.15 | -0.32 | -1.26% | 25.47 | 25.47 | 24.03 |
Jun 17, 2022 | 23.86 | 0.20 | 0.85% | 23.66 | 24.42 | 23.16 |
Jun 16, 2022 | 22.85 | -1.18 | -4.91% | 24.03 | 24.03 | 22.07 |
Jun 15, 2022 | 24.53 | 0.31 | 1.28% | 24.22 | 24.87 | 23.33 |
Jun 14, 2022 | 24.22 | 0.64 | 2.71% | 23.58 | 25.12 | 23.54 |
Jun 13, 2022 | 23.87 | -0.71 | -2.89% | 24.58 | 24.67 | 23.20 |
Jun 10, 2022 | 25.82 | -0.27 | -1.03% | 26.09 | 27.04 | 25.60 |
Jun 9, 2022 | 27.99 | 0.51 | 1.86% | 27.48 | 28.92 | 27.48 |
Jun 8, 2022 | 28.49 | 1.30 | 4.78% | 27.19 | 29.41 | 27.19 |
Jun 7, 2022 | 28.72 | 3.24 | 12.72% | 25.48 | 28.84 | 25.48 |
Jun 6, 2022 | 25.86 | -1.88 | -6.78% | 27.74 | 28.32 | 25.13 |
Jun 3, 2022 | 27.78 | 1.02 | 3.81% | 26.76 | 28.51 | 26.76 |
Jun 2, 2022 | 26.98 | 1.06 | 4.09% | 25.92 | 27.80 | 25.30 |
Jun 1, 2022 | 26.37 | 0.40 | 1.54% | 25.97 | 26.76 | 25.02 |
Cerevel Therapeutics Holdings, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Kogutulu | 0 | 0 | 0 |
Tulud majandustegevusest | -220.098 | -149.116 | 0 |
Jaotuse korrigeerimine | 0 | ||
Jaotamisele kuuluv netotulu | -225.334 | -148.271 | 0 |
Kogu tegevuskulu | 220.098 | 149.116 | |
Müük/Üldine/admin kulud, kokku | 58.243 | 45.813 | |
Uuringud ja arendus | 161.855 | 103.303 | |
Intressitulud (kulu), muud tulud, neto | 0.157 | 0.224 | |
Muud, neto | -5.393 | -3.274 | |
Netotulu enne makse | -225.334 | -152.166 | |
Netotulu pärast makse | -225.334 | -152.142 | |
Netotulu enne erikulusid | -225.334 | -152.142 | |
Netotulu | -225.334 | -152.142 | |
Total Adjustments to Net Income | 0 | 3.871 | |
Arvestatav tulu, v a erikulud | -225.334 | -148.271 | |
Arvestatav tulu, koos erikuludega | -225.334 | -148.271 | |
Keskmine jaotamisele kuuluv aktsia kohta | 136.577 | 73.6433 | |
Jaotatav EPS, v a erakorralised kulud | -1.64987 | -2.01337 | |
Jaotamisele kuuluv normaal-EPS | -1.64987 | -2.01337 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 72.53 | 64.49 | 54.527 | 50.51 | 50.571 |
Müük/Üldine/admin kulud, kokku | 17.507 | 16.649 | 14.368 | 13.216 | 14.01 |
Uuringud ja arendus | 55.023 | 47.841 | 40.159 | 37.294 | 36.561 |
Tulud majandustegevusest | -72.53 | -64.49 | -54.527 | -50.51 | -50.571 |
Intressitulud (kulu), muud tulud, neto | 0.295 | 0.119 | 0.013 | 0.01 | 0.015 |
Muud, neto | 3.941 | 5.316 | -7.545 | -2.739 | -0.425 |
Netotulu enne makse | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netotulu pärast makse | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netotulu enne erikulusid | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netotulu | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Arvestatav tulu, v a erikulud | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Arvestatav tulu, koos erikuludega | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Jaotamisele kuuluv netotulu | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Keskmine jaotamisele kuuluv aktsia kohta | 147.985 | 147.392 | 144.022 | 127.482 | 127.226 |
Jaotatav EPS, v a erakorralised kulud | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Käibevarad kokku | 578.017 | 390.56 | |
Raha ja lühiajalised investeeringud | 565.688 | 383.623 | |
Raha ja ekvivalendid | 193.018 | 383.623 | |
Prepaid Expenses | 11.6 | 6.777 | |
Other Current Assets, Total | 0.729 | 0.16 | |
Total Assets | 688.919 | 445.273 | |
Property/Plant/Equipment, Total - Net | 51.7 | 48.624 | |
Property/Plant/Equipment, Total - Gross | 54.266 | 48.706 | |
Accumulated Depreciation, Total | -2.566 | -0.082 | |
Other Long Term Assets, Total | 6.933 | 6.089 | |
Total Current Liabilities | 42.538 | 29.548 | |
Accounts Payable | 11.298 | 4.993 | |
Accrued Expenses | 30.865 | 24.282 | |
Notes Payable/Short Term Debt | 0 | 0 | |
Other Current Liabilities, Total | 0.375 | 0.273 | |
Total Liabilities | 110.19 | 60.753 | |
Total Long Term Debt | 33.54 | 0 | |
Other Liabilities, Total | 34.112 | 31.205 | |
Total Equity | 578.729 | 384.52 | |
Common Stock | 0.015 | 0.013 | |
Additional Paid-In Capital | 1195.94 | 775.417 | |
Retained Earnings (Accumulated Deficit) | -616.244 | -390.91 | |
Total Liabilities & Shareholders’ Equity | 688.919 | 445.273 | |
Total Common Shares Outstanding | 147.72 | 127.124 | |
Lühiajalised investeeringud | 372.67 | ||
Long Term Investments | 52.269 | ||
Long Term Debt | 33.54 | ||
Other Equity, Total | -0.986 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 553.55 | 578.017 | 675.029 | 331.782 | 349.811 |
Raha ja lühiajalised investeeringud | 542.944 | 565.688 | 669.676 | 327.06 | 343.287 |
Raha ja ekvivalendid | 91.764 | 193.018 | 669.676 | 327.06 | 343.287 |
Prepaid Expenses | 10.004 | 11.6 | 5.257 | 4.597 | 6.362 |
Other Current Assets, Total | 0.602 | 0.729 | 0.096 | 0.125 | 0.162 |
Total Assets | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
Property/Plant/Equipment, Total - Net | 52.663 | 51.7 | 51.98 | 51.92 | 51.784 |
Property/Plant/Equipment, Total - Gross | 56.299 | 54.266 | 53.526 | 52.552 | 51.876 |
Accumulated Depreciation, Total | -3.636 | -2.566 | -1.546 | -0.632 | -0.092 |
Other Long Term Assets, Total | 4.411 | 6.933 | 6.471 | 7.302 | 6.509 |
Total Current Liabilities | 35.318 | 42.538 | 30.8 | 29.257 | 34.151 |
Accounts Payable | 8.183 | 11.298 | 5.445 | 4.986 | 7.755 |
Accrued Expenses | 26.442 | 30.865 | 24.928 | 23.939 | 26.241 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.693 | 0.375 | 0.427 | 0.332 | 0.155 |
Total Liabilities | 97.053 | 110.19 | 104.4 | 97.117 | 68.068 |
Total Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | 0 |
Other Liabilities, Total | 33.411 | 34.112 | 34.988 | 35.618 | 33.917 |
Total Equity | 521.499 | 578.729 | 629.08 | 293.887 | 340.036 |
Common Stock | 0.015 | 0.015 | 0.015 | 0.013 | 0.013 |
Additional Paid-In Capital | 1207.36 | 1195.94 | 1186.79 | 789.004 | 781.914 |
Retained Earnings (Accumulated Deficit) | -684.538 | -616.244 | -557.189 | -495.13 | -441.891 |
Total Liabilities & Shareholders’ Equity | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
Total Common Shares Outstanding | 148.183 | 147.72 | 147.136 | 127.585 | 127.325 |
Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | |
Other Equity, Total | -1.334 | -0.986 | -0.533 | ||
Lühiajalised investeeringud | 451.18 | 372.67 | |||
Long Term Investments | 7.928 | 52.269 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | |
---|---|---|---|
Netotulu/algväärtus | -225.334 | -152.142 | |
Raha majandustegevusest | -178.546 | -117.802 | |
Raha majandustegevusest | 2.731 | 0.397 | |
Mittelikviidsed varad | 28.516 | 16.236 | |
Muutused tööjõus | 15.541 | 17.707 | |
Tulu investeeringutelt | -435.661 | -18.892 | |
Kapitalikulutused | -10.503 | -18.892 | |
Rahavood investeeringutelt | 423.602 | 440.835 | |
Rahavoogudesse investeerimine | -0.355 | 440.835 | |
Rahaline kogumuutus | -190.605 | 304.141 | |
Muud rahavood investeeringutelt, kokku | -425.158 | ||
Aktsiate emiteerimine (tagasiost), neto | 392.707 | ||
Laenu väljastamine (kustutamine), neto | 31.25 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -68.294 | -225.334 | -166.279 | -104.22 | -50.981 |
Cash From Operating Activities | -67.648 | -178.546 | -125.802 | -82.026 | -36.418 |
Cash From Operating Activities | 1.118 | 2.731 | 1.644 | 0.664 | 0.063 |
Non-Cash Items | 4.935 | 28.516 | 27.551 | 14.084 | 6.377 |
Changes in Working Capital | -5.407 | 15.541 | 11.282 | 7.446 | 8.123 |
Cash From Investing Activities | -38.542 | -435.661 | -9.431 | -8.243 | -4.66 |
Capital Expenditures | -2.197 | -10.503 | -9.431 | -8.243 | -4.66 |
Cash From Financing Activities | 2.603 | 423.602 | 421.286 | 33.706 | 0.742 |
Issuance (Retirement) of Stock, Net | 2.854 | 392.707 | 390.036 | 2.571 | 0.742 |
Net Change in Cash | -103.587 | -190.605 | 286.053 | -56.563 | -40.336 |
Financing Cash Flow Items | -0.251 | -0.355 | 0 | -0.115 | |
Issuance (Retirement) of Debt, Net | 31.25 | 31.25 | 31.25 | ||
Other Investing Cash Flow Items, Total | -36.345 | -425.158 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Bain Capital Private Equity, LP | Private Equity | 38.704 | 60632356 | 0 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 17.4581 | 27349211 | 0 | 2022-08-16 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 14.5879 | 22852917 | 67107 | 2022-12-31 | LOW |
Perceptive Advisors LLC | Private Equity | 4.1567 | 6511727 | 0 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8476 | 6027510 | 164460 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 3.027 | 4742044 | 1202 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2049 | 3454078 | 288570 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.1858 | 3424220 | 704948 | 2022-12-31 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 1.8304 | 2867451 | -445882 | 2022-12-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.6 | 2506464 | 7316 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.2806 | 2006068 | 4631 | 2022-12-31 | MED |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.2128 | 1900000 | -100000 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7686 | 1204108 | 69847 | 2022-12-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.7349 | 1151321 | -231639 | 2022-12-31 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 0.7159 | 1121566 | 35610 | 2022-12-31 | MED |
Hood River Capital Management LLC | Investment Advisor | 0.5896 | 923638 | 27066 | 2022-12-31 | MED |
Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 0.5716 | 895509 | -87899 | 2022-12-31 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.4755 | 744853 | 7881 | 2022-12-31 | LOW |
Novalis LifeSciences LLC | Private Equity | 0.4043 | 633350 | 0 | 2022-03-31 | |
Fidelity Institutional Asset Management | Investment Advisor | 0.3602 | 564215 | 34460 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cerevel Therapeutics Holdings, Inc. Company profile
Ettevõttest Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte ühendab uute ravimeetodite avastamiseks ja väljatöötamiseks haigusega seotud bioloogia ja aju neurotsirkulatsiooni mõistmise keemia ja kesknärvisüsteemi (KNS), retseptorite farmakoloogiaga. Ettevõte tegeleb uute ravimeetodite väljatöötamisega neuroteaduslike haiguste, sealhulgas skisofreenia, epilepsia ja Parkinsoni tõve raviks. Ettevõtte tootekandidaatide hulka kuuluvad CVL-231, Darigabat, Tavapadon, CVL-871 ja CVL-936. Ettevõtte tootekandidaat CVL-231 skisofreenia raviks. Tema Darigabat nii epilepsia kui ka ärevuse raviks. Tavapadon on dopamiini D1/D5 osaline agonist varajase ja hilisema staadiumi Parkinsoni tõve raviks. Tema tootekandidaat CVL-871 dementsusega seotud apaatia raviks. CVL-936 ainete tarvitamise häire raviks.
Industry: | Bio Therapeutic Drugs |
222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com